Our drug candidates

AON-D21 (anti-C5a): Our lead program is in Phase 1 clinical development. In a single-ascending dose study in healthy volunteers, AON-D21 was shown to be safe and well tolerated. A multiple-ascending dose study will be completed mid 2022.

Efficacy of AON-D21 and related L‑aptamers was shown in various preclinical studies, including translational models of pneumonia and sepsis, and in lung cancer, most effectively in combination with immune checkpoint inhibition.

The broad role of the target C5a as an orchestrator of the human immune system holds promise to expand the indication spectrum into further diseases where immune modulation is desirable.

AON-S08 (anti-IL8): AON-S08 is a sub-nanomolar inhibitor of interleukin-8 (also called CXCL8). This drug candidate is evaluated in preclinical studies.